Biotech Radar — August 5, 2026: $OBX, $ACRV and $URGN Lead a Broad Clinical and Capital-Markets Tape
Three developments define today’s secondary-biotech tape: Obsidian moves amsoki-cel into a registration-enabling melanoma cohort, Acrivon advances ACR-2316 into randomized dose expansion, and UroGen reports a sharp commercial acceleration for ZUSDURI. Beneath those headlines, the day also delivered new trial starts, commercial-launch metrics, an in-licensing transaction, a biotech IPO and a sizeable follow-on offering.
Merlintrader biotech updates: follow the English-language channel for new research and catalyst alerts.
This Radar is deliberately focused on companies that do not already have a dedicated Merlintrader Stock Hub. The objective is not to rank stocks by short-term upside. It is to separate genuinely decision-relevant developments from routine corporate noise, identify what changed, and define the next evidence point that can confirm or weaken each story.
Today’s market signal: the strongest items are not all clinical readouts. The tape spans a registration path, an early clinical expansion, a commercial launch, new trial execution and fresh equity capital. That breadth matters because it shows risk appetite extending beyond a single disease area or catalyst type.
01
August 5 biotech tape at a glance
$OBX
Registration path
First patient in the amsoki-cel registration-enabling cohort
FDA alignment supports a single-arm design intended to contribute to a future BLA in checkpoint-inhibitor-resistant advanced melanoma.
$ACRV
Clinical expansion
ACR-2316 enters randomized dose expansion
Acrivon selected 120 mg and 160 mg weekly regimens after observing early single-agent activity and a manageable hematologic safety profile.
$URGN
Commercial inflection
ZUSDURI revenue reaches $50.4 million
Second-quarter ZUSDURI revenue increased 73% sequentially, while repeat prescribers represented roughly 45% of total prescribers.
| Company | Development | What changes | Signal |
|---|---|---|---|
| $OBX | Registration-enabling melanoma cohort starts | Moves amsoki-cel from proof-of-concept toward a potential accelerated-approval package | Lead |
| $ACRV | Randomized ACR-2316 dose expansion | Begins formal optimization of dose and tumor-type selection | Lead |
| $URGN | Q2 commercial update | ZUSDURI becomes the main revenue engine and adds patent visibility | Lead |
| $DMRA | CLARITY-101 Phase 1/1b starts | First clinical test of once-monthly anti-mutCALR antibody DMR-001 | Watch |
| $SPRC | Yale site starts Phase 2b work | Adds the U.S. center to the SCI-110 Tourette program | Watch |
| $IMRX | Q2 update | Confirms Phase 3 MAPKeeper 301 execution and runway into 2029 | Watch |
| $IMA | Q2 update | ADAPTIVE continues; the major readout remains distant | Watch |
| $ETON | ASN-001 U.S. rights acquired | Adds a late-stage topical infantile-hemangioma opportunity | Watch |
| $CTOR | LYMPHIR launch metrics | Shows broader institutional access and vial demand | Watch |
| $TWST | $300 million follow-on priced | Adds capital for R&D, manufacturing and products, with dilution | Capital |
| $ATTO | $289 million upsized IPO priced | Creates a new public immunology platform with substantial funding | Capital |
| $PACB | Vega performance update | Improves throughput and workflow controls in long-read sequencing | Tools |
02
The three developments that lead today’s Radar
$OBX
Obsidian starts the registration-enabling amsoki-cel cohort
A development-stage TIL program crosses into a clearly defined regulatory execution phase.
What happened. Obsidian Therapeutics enrolled the first patient in the registration-enabling cohort of Agni-01, its Phase 1/2 study of amsokigene autoleucel, or amsoki-cel, in immune-checkpoint-inhibitor-resistant advanced or metastatic melanoma. Following discussions with the FDA, the company selected a single-arm cohort intended to support a future biologics license application and an accelerated-approval pathway. The primary endpoint is objective response rate under RECIST 1.1, assessed by blinded independent central review.
Why it matters. Earlier Agni-01 results at the recommended Phase 2 dose showed a 67% objective response rate in 15 patients, with 10 responses including two complete responses. The importance of today’s announcement is not a new response-rate number; it is the translation of that initial signal into a registrational strategy. The proposed treatment model also tries to reduce some practical friction associated with traditional TIL therapy through an IL-2-free regimen, low-dose lymphodepletion and the option of core-needle-biopsy tissue procurement.
Investor interpretation. The regulatory alignment reduces trial-design ambiguity but does not remove clinical or manufacturing risk. A 15-patient efficacy set remains small, and single-arm accelerated approval will depend on the magnitude, durability and independent confirmation of responses in a larger population. Cell-therapy consistency, turnaround and center-level execution remain central parts of the thesis.
Next catalyst
Enrollment completion is targeted by the end of Q1 2027; topline registration-enabling data are expected by year-end 2027. Phase 1 NSCLC data are expected in the first half of 2027.
Main risk
The earlier 67% ORR comes from a small cohort. Response durability, manufacturing reproducibility and FDA acceptance of the final package remain unproven.
What to monitor
Enrollment pace, any change to the single-arm design, duration-of-response disclosures and evidence that the outpatient-compatible regimen works across treatment centers.
Verified source
Obsidian Therapeutics release distributed through Business Wire, August 5, 2026; Agni-01 registry NCT06060613.
$ACRV
Acrivon advances ACR-2316 into randomized dose expansion
The program now has to show that its early cross-tumor activity can survive structured dose optimization.
What happened. Acrivon moved ACR-2316, an oral dual WEE1/PKMYT1 inhibitor designed with the company’s AP3 phosphoproteomic platform, into randomized dose expansion. The study will compare 120 mg and 160 mg once-daily doses on a three-days-on, four-days-off weekly schedule across AP3-informed tumor types, including small-cell lung cancer, squamous and adenocarcinoma non-small-cell lung cancer, endometrial cancer, cervical cancer and esophagogastric-junction cancer.
Why it matters. In dose escalation, 35 patients received ACR-2316 across six dose levels. Among seven efficacy-evaluable patients with the selected lung-cancer histologies, the company reported an 86% disease-control rate: two partial responses, four stable-disease cases and one progressive-disease case. Three heavily pretreated lung-cancer patients remained on therapy for more than one year. At the selected doses, no Grade 4 or higher treatment-related adverse event was reported; Grade 3 events were mainly transient hematologic toxicities, particularly neutropenia.
Investor interpretation. The attraction is a single-agent signal in tumor types not generally viewed as established single-agent WEE1 or PKMYT1 settings. The limitation is the extremely early denominator. Randomized dose expansion is therefore less about confirming the headline disease-control rate and more about identifying a dose with a repeatable benefit-risk profile across larger, prospectively selected cohorts.
Next catalyst
Dose-expansion enrollment and the next clinical data update, particularly response durability and performance by tumor cohort.
Main risk
Small cohorts can overstate efficacy. Neutropenia may also constrain dose intensity as patient numbers rise.
What to monitor
Confirmed versus unconfirmed responses, duration of treatment, discontinuations, dose reductions and whether AP3 selection produces consistent enrichment.
Verified source
Acrivon Therapeutics investor-relations release, August 5, 2026, read against the company’s January 8, 2026 dose-escalation disclosure.
$URGN
UroGen’s ZUSDURI launch becomes a commercial-growth story
Sequential adoption, repeat prescribing and longer patent visibility strengthen the franchise narrative.
What happened. UroGen reported second-quarter 2026 total revenue of $72.5 million, compared with $24.2 million in the prior-year quarter. ZUSDURI generated $50.4 million of net product revenue, up 73% from the first quarter, while JELMYTO contributed $22.0 million. At June 30, the company reported 1,444 activated sites of care, 452 unique ZUSDURI prescribers and 204 repeat prescribers, meaning repeat prescribers represented about 45% of the total.
Why it matters. Repeat prescribing is more informative than a launch-quarter shipment spike because it begins to test whether physicians are incorporating the product into routine practice. The company also received a U.S. patent notice of allowance expected, once issued, to protect methods covering ZUSDURI and UGN-103 into July 2044. In addition, updated ENVISION data showed an estimated 64.5% duration-of-response rate at 36 months among patients who had achieved a complete response at three months.
Financial context. UroGen ended June with $108.0 million in cash, cash equivalents and marketable securities. The company reported a $14.4 million quarterly net loss, materially narrower than the $49.9 million loss in the prior-year quarter, and reiterated 2026 JELMYTO revenue guidance of $97 million to $101 million. The launch is strengthening the income statement, but sustained commercial spending and pipeline investment still matter when judging future financing needs.
Next catalyst
UGN-103’s NDA remains targeted for Q3 2026, while UGN-501 is expected to begin Phase 1 in Q4 2026.
Main risk
Sequential launch growth can normalize quickly. Reimbursement execution, persistence of repeat use and operating-expense discipline must confirm the early trajectory.
What to monitor
Quarterly ZUSDURI demand, repeat-prescriber share, gross-to-net dynamics, JELMYTO stability and the timing of patent issuance.
Verified source
UroGen Pharma investor-relations release and Q2 2026 financial disclosure, August 5, 2026.
03
Secondary news: the rest of today’s biotech tape
Clinical start
$DMRA — CLARITY-101 begins testing DMR-001
Damora initiated the global Phase 1/1b CLARITY-101 study in mutant-CALR-driven essential thrombocythemia and myelofibrosis. The open-label study starts at 100 mg monthly by subcutaneous injection and uses adaptive dose escalation before planned expansion. DMR-001 is designed to cover Type 1 and non-Type 1 CALR mutations while sparing wild-type calreticulin.
Next: initial clinical data are expected beginning in mid-2027. Risk: the potency and long half-life remain preclinical claims until human safety, pharmacokinetics and activity are shown.
Site activation
$SPRC — Yale joins the SCI-110 Phase 2b program
SciSparc said NeuroThera Labs started Phase 2b work at the Yale Child Study Center for SCI-110 in adults with Tourette syndrome. The randomized, double-blind, placebo-controlled crossover study also includes sites in Germany and Israel. The official registry lists an estimated 164 participants and measures tic severity at weeks 12 and 26.
Next: recruitment progress and the registered primary-completion window in 2027. Risk: the cited 21% average tic reduction comes from an earlier small study and needs placebo-controlled confirmation.
Late-stage execution
$IMRX — Phase 3 execution, not a new efficacy readout
Immuneering’s Q2 update reiterated the 17.3-month median overall survival previously presented at ASCO in 55 first-line metastatic pancreatic-cancer patients receiving atebimetinib plus modified gemcitabine/nab-paclitaxel. The genuinely current development is operational: the pivotal MAPKeeper 301 study is dosing patients and has more than 30 study locations posted. Cash and securities totaled $182.7 million at June 30, with company guidance pointing to runway into 2029.
Next: Phase 3 enrollment progress. Risk: the Phase 2a dataset was single-arm; randomized evidence is still required.
Pipeline update
$IMA — OX40 program advances, but the readout is distant
ImageneBio said the amended Phase 2b ADAPTIVE study of olevaprubart in moderate-to-severe atopic dermatitis is progressing and its long-term-extension study is enrolling. The independent monitoring committee recommended continuation without changes. A Phase 2 alopecia-areata study is planned to start in 2026. Cash and securities were $136.2 million at June 30, with projected runway into Q1 2028.
Next: EADV presentations and the alopecia-areata trial start; ADAPTIVE topline data are expected in Q4 2027. Risk: the long wait to pivotal evidence leaves execution and financing sensitivity.
Business development
$ETON — ASN-001 expands the infantile-hemangioma franchise
Eton licensed U.S. rights to ASN-001, a topical timolol gel for proliferating superficial infantile hemangiomas. A completed 168-patient Phase 2/3 study showed elimination or near-elimination at week 24 in 56% of twice-daily patients and 42% of three-times-daily patients, versus 15% on placebo. Eton plans a bioavailability bridging study before an NDA.
Next: NDA submission is targeted for the second half of 2027, with potential approval and launch in 2028. Risk: the bridging and regulatory path must support reliance on the existing study, and commercial uptake is not yet demonstrated.
Commercial launch
$CTOR — LYMPHIR broadens institutional adoption
Citius Oncology reported LYMPHIR availability at 42 institutions. New institutional accounts increased 78% quarter over quarter and vial orders placed by institutions with wholesalers increased 31%. The company said payer coverage is near universal and expects more than 20 additional institutions during the current quarter.
Next: the company targets formulary inclusion at 100 priority institutions by year-end. Risk: formulary access and wholesaler orders must convert into durable patient demand and recognized revenue.
Follow-on offering
$TWST — an upsized $300 million equity raise
Twist Bioscience priced 3.125 million common shares at $96.00, producing expected gross proceeds of $300 million before fees. The underwriters received a 30-day option for another 468,750 shares. Twist intends to fund R&D, manufacturing-capacity expansion, product offerings and general corporate purposes.
Next: closing is expected August 6, subject to customary conditions. Risk: existing holders absorb dilution; the analytical question is whether incremental investment produces returns above the added share count.
Initial public offering
$ATTO — Attovia prices an upsized $289 million IPO
Attovia priced 17 million shares at $17.00 for expected gross proceeds of $289 million, plus an underwriter option for up to 2.55 million additional shares. Trading is expected to begin on Nasdaq under $ATTO. The platform targets immune-mediated diseases through biparatopic and multispecific biologics, led by the clinical-stage anti-IL-31 program ATTO-1310.
Next: expected closing on August 6 and the first public-company clinical milestones. Risk: this is a newly public, development-stage platform with execution, lock-up and valuation-discovery risk.
Genomics tools
$PACB — Vega receives a throughput and workflow update
PacBio announced faster run configurations, up to 50% more HiFi data in specified workflows and new compliance controls for the Vega sequencing system. The update is commercially relevant because instrument productivity, workflow simplicity and regulated-lab compatibility influence adoption beyond headline sequencing accuracy.
Next: customer uptake and evidence that higher throughput improves consumables pull-through. Risk: technical improvements do not automatically translate into placements, utilization or better margins.
04
How to read this mixed biotech tape
1. Separate data from execution
$OBX and $ACRV are advancing programs because of earlier clinical signals, but today’s announcements are primarily execution milestones. The next datasets, not the press releases themselves, must validate the implied value.
2. Commercial breadth needs repetition
$URGN and $CTOR show encouraging adoption markers. The strongest confirmation would be repeat use, clean revenue conversion and stable reimbursement over multiple quarters rather than one launch-period comparison.
3. Capital is both fuel and a claim on value
$TWST and $ATTO demonstrate access to sizeable equity financing. That reduces near-term funding risk, but dilution and capital efficiency remain part of the return equation.
The most decision-useful question is therefore not “which headline is positive?” It is “what evidence must arrive next, when is it expected, and what would invalidate the current interpretation?” That keeps a diversified news day from becoming a list of disconnected press releases.
05
Primary sources and verification notes
- Obsidian Therapeutics: first patient in the amsoki-cel registration-enabling cohort, August 5, 2026; Agni-01 registry.
- Acrivon Therapeutics: ACR-2316 randomized dose expansion, August 5, 2026.
- UroGen Pharma: Q2 2026 financial results and ZUSDURI update, August 5, 2026.
- Damora Therapeutics company release on CLARITY-101, August 5, 2026; supporting program background cross-checked against the company’s SEC registration disclosures.
- SciSparc/NeuroThera company release, August 5, 2026; official SCI-110 Phase 2 registry.
- Immuneering: Q2 2026 financial results and business update, August 5, 2026.
- ImageneBio company release on Q2 2026 results, August 5, 2026; ADAPTIVE long-term-extension registry.
- Eton Pharmaceuticals: U.S. rights to ASN-001, August 5, 2026.
- Citius Oncology company release on LYMPHIR commercial momentum, August 5, 2026.
- Twist Bioscience: pricing of upsized $300 million public offering, August 4, 2026.
- Attovia Therapeutics company release on pricing of its upsized initial public offering, August 4, 2026.
- PacBio company release on Vega performance and compliance updates, August 5, 2026.
Transparency: all figures in the analysis are attributed to company releases, regulatory filings or official trial registries. Company targets and efficacy statements are not independent forecasts. Where no new efficacy dataset was released, the text labels the item as execution, financing or commercial news rather than presenting it as a clinical readout.
Follow the full biotech research map
Use the Biotech Stocks Hub to navigate Merlintrader’s company research, and follow the English-language Telegram channel for new Radar posts and catalyst updates.
Merlintrader community: continue the discussion on r/MerlintraderPub or follow @merlintraderpub_com.
Disclaimer: This material is provided solely for educational and informational purposes and does not constitute investment advice, financial advice, a recommendation, an offer or a solicitation to buy or sell any security. Biotech securities can be highly volatile and may react sharply to clinical, regulatory, financing and commercial developments. Company statements may contain forward-looking information and may not be achieved. Readers should verify current filings and official disclosures, conduct their own research and consult an appropriately registered financial professional. Nothing in this article is individualized advice under U.S. securities laws or SEC standards. See the full Merlintrader disclaimer.
Track the next biotech catalyst
Follow upcoming PDUFA decisions, AdCom meetings, clinical readouts and trial milestones in the free Merlintrader Biotech Catalyst Calendar.